<DOC>
	<DOCNO>NCT02061423</DOCNO>
	<brief_summary>The primary goal trial determine safety immune activity HER-2 pulse DC1 vaccine patient high risk HER-2pos breast cancer residual disease post neoadjuvant therapy . Investigators also explore possibility determine whether circulate tumor cell use surrogate assess response vaccination .</brief_summary>
	<brief_title>HER-2 Pulsed DC Vaccine Prevent Recurrence Invasive Breast Cancer Post Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>Dendritic cell cancer vaccine combine chemotherapy may increase complete response give breast cancer specific immune cell great opportunity function immune repertoire shift chemotherapy anti-breast cancer response offer chance test secondary prevention breast cancer high risk setting . There need determine whether ICAIT DC1 activate CD4 CD8 T cell prior combination chemotherapy without added trastuzumab . This study begin Abramson Cancer Center University Pennsylvania continue H. Lee Moffitt Cancer Center Research Institute .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Women â‰¥ 18 year . HER2 express stage I III breast cancer residual disease breast axillary node postneoadjuvant chemotherapy . Women childbearing age negative pregnancy serum test document prior enrollment . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score 0 1 . Women childbearing potential must agree use medically acceptable form birth control participation study . Have voluntarily sign write Informed Consent accordance institutional policy content fully explain . Pregnant lactating . Positive HIV hepatitis C baseline self report . Potential participant coagulopathies , include thrombocytopenia platelet count &lt; 75,000 , INR &gt; 1.5 partial thromboplastin time &gt; 50 sec . Potential participant MUGA &lt; 50 % EF . Preexisting medical illness medication might interfere study determine Principal Investigator ( PI ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Invasive Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dendritic Cell</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>